# A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct06395519/  
OnCo record `nct06395519` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ETX-19477 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by 858 Therapeutics, Inc., now recruiting.

## Summary

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06395519 by 858 Therapeutics, Inc., with 120 participants planned, started 2024-05-13 and due to reach its primary completion in 2026-12. Interventions recorded: ETX-19477.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06395519
- Phase: 1/2
- Setting: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Sponsor: 858 Therapeutics, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06395519: https://clinicaltrials.gov/study/NCT06395519

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06395519.json